Clinical Research Directory
Browse clinical research sites, groups, and studies.
Research for the Molecular Imaging of the HER2 Targeting Tracer
Sponsor: Peking University Cancer Hospital & Institute
Summary
To use the molecular PET radionuclide (Ga-68 or F-18) labelled HER2 Affibody to detect the expression of HER2 in the primary and metastatic lesions in patients with HER2 positive or suspicious positive tumors; to detect the expression heterogeneity of HER2 in the lesions and inter-lesions; to observe the change of HER2 expression in the course of treatment. To provide an approach for screening patients high expression of HER2, efficacy monitoring, drug resistance and early warning of recurrence and metastasis to achieve the individualized antitumor treatment of targeted drugs.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2020-09-07
Completion Date
2026-08-30
Last Updated
2025-03-21
Healthy Volunteers
No
Interventions
68Ga/18F-HER2 Affibody PET/CT scan
HER2 Affibody, labeled with PET radio-nuclide ( 68Ga or F-18) will be used as a molecular imaging tracer for PET/CT scan. All participants will undergo 68Ga/18F-HER2 Affibody PET/CT scan.
Locations (1)
Hua Zhu
Beijing, Beijing Municipality, China